Nexstim
€2.3m rights issue is 273% subscribedNexstim
Hitting the right spotNexstim
€2.3m rights issue to progress both NBS and NBTNexstim
Patient registry shows promising outcomes in MDDNexstim
Focussing on strategic prioritiesNexstim
Licensing discussions with academic centre endNexstim
Making an impression in depressionNexstim
Warrants to be topped up with share placementNexstim
Q319 update shows therapy business momentumNexstim
A possible new opportunity in severe depression